PHASE-I STUDY OF DIVIDED-DOSE VINBLASTINE IN ADVANCED MALIGNANCY

  • 1 January 1985
    • journal article
    • research article
    • Vol. 69  (6) , 607-610
Abstract
Thirty-one patients with advanced malignancy received vinblastine as an i.v. bolus at 0 and 48 h of a 21-day cycle. Divided-dose vinblastine may be given with acceptable toxicity in heavily pretreated patients; leukopenia and neuropathy were the dose-limiting toxic effects. One patient with breast cancer and 1 with ovarian cancer responded. Serum vinblastine levels with this program approximate those achieved by a 5-day continuous infusion of vinblastine in standard dose.

This publication has 0 references indexed in Scilit: